Key facts
- Qkine’s last known valuation is $15.7M (Mar 2025).
- It has raised $9.7M; the latest was Later Stage VC ($1.4M) in Mar 2025.
- Notable investors include Innovate UK, Parkwalk Advisors, Cambridge Angels, Cambridge Enterprise Ventures, Meltwind Advisory — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Qkine
- ·The full record, as it builds
Funding rounds
No funding rounds for Qkine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Qkine
Manufacturer of cytokines and complex proteins intended to advance stem cell, organoid, and regenerative medicines. The company manufactures high-purity, animal-free growth factors, cytokines, and proteins for life science applications, including organoid culture, and combines proprietary production processes with protein engineering technology to tackle fundamental biological and scale-up challenges, enabling clients with the highest purity, bioactive proteins to support its customers best and maximize the impact of their science.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2016
- Employees
- 36
- Website
- qkine.com/
- Ownership
- Privately Held (backing)
Qkine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qkine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qkine in its N-PORT filings yet. We sweep new filings monthly.